End-of-day quote
Other stock markets
|
||
- | - |
2023 | Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA | CI |
2023 | ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
Sales 2024 * | 78.73B 56.85M 0 4.48B | Sales 2025 * | 170B 122M 0 9.65B | Capitalization | 9,876B 7.13B 0 562B |
---|---|---|---|---|---|
Net income 2024 * | 7B 5.05M - 398M | Net income 2025 * | 50B 36.1M - 2.84B | EV / Sales 2024 * | 125 x |
Net cash position 2024 * | 36.8B 26.57M 0 2.09B | Net cash position 2025 * | 59.2B 42.74M 0 3.37B | EV / Sales 2025 * | 57.9 x |
P/E ratio 2024 * |
1,377
x | P/E ratio 2025 * |
193
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.57% |
Managers | Title | Age | Since |
---|---|---|---|
Sun-Jae Park
CEO | Chief Executive Officer | 69 | 12/05/08 |
Sang-Woo Kang
DFI | Director of Finance/CFO | 58 | 31/05/20 |
Gyu-Wan Kim
CTO | Chief Tech/Sci/R&D Officer | 58 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Sun-Jae Park
CEO | Chief Executive Officer | 69 | 12/05/08 |
Jong-In Choi
BRD | Director/Board Member | 59 | 28/03/21 |
In-Young Go
BRD | Director/Board Member | 68 | 28/03/21 |
1st Jan change | Capi. | |
---|---|---|
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |